NEW YORK (TheStreet) -- Corcept Therapeutics (CORT - Get Report) plummeted Wednesday after the company stopped a late-stage trial of its depression treatment drug Mifepristone after analysis determined it was unlikely to succeed.
Data analysis from the first 226 patients enrolled in the trial determined the drug did not significantly reduce psychotic depression symptoms. An independent safety committee analyzed the data and suggested stopping the trial because it was unlikely to produce positive results.
Corcept announced it would halt the trial to shift its focus to other, potentially more fruitful programs, especially in oncology.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts